Insulin absorption accelerated by alpha-adrenergic blockade at injection site

Area of Science:

• Pharmacology
• Endocrinology
• Metabolism

Background:

• Insulin therapy is crucial for managing diabetes.
• Optimizing insulin absorption can improve glycemic control.
• Alpha-adrenergic blockers like phenoxybenzamine may influence insulin pharmacokinetics.

Purpose of the Study:

• To investigate the effect of phenoxybenzamine on insulin absorption and plasma glucose levels.
• To determine if phenoxybenzamine enhances insulin bioavailability.
• To assess the impact on glycemic response in healthy individuals.

Main Methods:

• Five normal subjects received subcutaneous insulin (0.2 U/kg) with or without phenoxybenzamine (20 micrograms).
• Insulin absorption and plasma glucose concentrations were monitored over 180 minutes.
• Pharmacokinetic and glycemic parameters were analyzed.

Main Results:

• Phenoxybenzamine significantly accelerated insulin absorption, leading to higher peak insulin levels at 45 minutes.
• Plasma glucose concentrations decreased more rapidly and reached lower nadirs with phenoxybenzamine.
• Two subjects experienced hypoglycemic symptoms, indicating a potent glucose-lowering effect.

Conclusions:

• Phenoxybenzamine enhances the bioavailability of subcutaneously injected insulin for at least 3 hours.
• The addition of phenoxybenzamine results in a more pronounced reduction in plasma glucose concentrations.
• Further research is needed to evaluate the safety and efficacy in diabetic patients.